FIRSTLY – Efficient routine production (100mg to grams) of recombinant viral proteins and monoclonal antibodies for TEST KITS to assess the immune response to SARS-CoV-2 in the population.
Also, mAbs for the quantification and characterisation of VACCINES prior to lot release :

https://www.kdbio.com/applications/produce-difficult-to-express-recombinant-protein

https://www.kdbio.com/applications/monoclonal-antibodies/.

SECONDLY – Antimicrobial pharmacodynamics and evaluation of the emergence of resistance. Publications include:

Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system: Pires de Mello, C.P.; European Journal of Pharmaceutical Sciences 111 (2018) 443-449 [open access]

Azithromycin Pharmacodynamics Against Non-Typeable H. Influenzae: Fisher, J., Yale University Public Health Theses 2016 [open access]

THIRDLY– Production of SARS-CoV-2 virus in the laboratory at high titer

https://www.kdbio.com/applications/references-virus-production.

FOURTHLY – Rapid production of exosomes for inhalation therapy, perhaps, or for novel vaccines:

https://www.kdbio.com/applications/exosome-extracellular-vesicle-production/.